New Conus-derived alpha-conotoxin analgesics for the treatment of chronic pain: structure, mode of action, delivery and disposition. Current product deficiencies in the area of pain management are forcing the pharmaceutical industry to develop new strategies for achieving analgesia and reduce their dependence on traditional, addictive opiate-based products. Structural modification of cone snail derived peptides will provide exciting new leads for achieving effective analgesia.